Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low vs Standard Dose Albumin in SBP
NCT04273373Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients having new development or progression of Acute Kidney Injury at Day 7. Started Mar 2020; status: completed.
02
Drugs
albumin (human)
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT04273373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273373.